Klesel N, Limbert M, Schrinner E, Seeger K, Seibert G, Winkler I
Infection. 1984 Jul-Aug;12(4):286-92. doi: 10.1007/BF01645963.
The chemotherapeutic properties of the new aminothiazolyl cephalosporin HR810 were investigated in experimental animals. Unlike other cephalosporins of the third generation, HR810 had good activity against Staphylococcus aureus as well as some activity against enterococci. In murine protection tests with these strains, it was clearly superior to ceftazidime, cefotaxime, ceftriaxone, cefoperazone and latamoxef. The compounds most effective in protecting mice from infections caused by Enterobacteriaceae were HR810 and ceftriaxone followed by ceftazidime, latamoxef and cefotaxime; cefoperazone was less active. HR810 was less active against Pseudomonas aeruginosa than ceftazidime but was considerably more effective than the other cephalosporins tested. HR810 also proved effective against localised infections such as thigh lesions, as well as against meningo-encephalitis in mice and pyelonephritis in rats. These results in laboratory animals make HR810 a promising candidate for clinical studies.
在实验动物身上研究了新型氨基噻唑基头孢菌素HR810的化疗特性。与其他第三代头孢菌素不同，HR810对金黄色葡萄球菌具有良好的活性，对肠球菌也有一定活性。在用这些菌株进行的小鼠保护试验中，它明显优于头孢他啶、头孢噻肟、头孢曲松、头孢哌酮和拉氧头孢。在保护小鼠免受肠杆菌科细菌感染方面最有效的化合物是HR810和头孢曲松，其次是头孢他啶、拉氧头孢和头孢噻肟；头孢哌酮的活性较低。HR810对铜绿假单胞菌的活性低于头孢他啶，但比其他受试头孢菌素有效得多。HR810还被证明对局部感染有效，如大腿损伤，以及对小鼠的脑膜脑炎和大鼠的肾盂肾炎也有效。这些在实验动物身上的结果使HR810成为临床研究的一个有前景的候选药物。
